MX2016010179A - Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. - Google Patents

Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.

Info

Publication number
MX2016010179A
MX2016010179A MX2016010179A MX2016010179A MX2016010179A MX 2016010179 A MX2016010179 A MX 2016010179A MX 2016010179 A MX2016010179 A MX 2016010179A MX 2016010179 A MX2016010179 A MX 2016010179A MX 2016010179 A MX2016010179 A MX 2016010179A
Authority
MX
Mexico
Prior art keywords
donepezil
disease
treating alzheimer
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2016010179A
Other languages
English (en)
Inventor
Vermani Kavita
G Dedhiya Mahendra
Katdare Ashok
Original Assignee
Forest Laboratories Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53753905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories Holdings Ltd filed Critical Forest Laboratories Holdings Ltd
Publication of MX2016010179A publication Critical patent/MX2016010179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporcionan formas farmacéuticas orales que comprenden donepezilo o una sal farmacéuticamente aceptable de este (p. ej., clorhidrato de donepezilo) solo o junto con un segundo ingrediente activo (p. ej., clorhidrato de memantina o una sal farmacéuticamente aceptable de esta) para el tratamiento de la enfermedad de Alzheimer. Las formas farmacéuticas orales comprenden gránulos de donepezilo que se pueden esparcir en la comida y pueden mejorar considerablemente la cooperación en los pacientes con dificultad de deglución.
MX2016010179A 2014-02-04 2015-02-04 Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. MX2016010179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935596P 2014-02-04 2014-02-04
PCT/US2015/014404 WO2015120013A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2016010179A true MX2016010179A (es) 2017-04-06

Family

ID=53753905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010179A MX2016010179A (es) 2014-02-04 2015-02-04 Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.

Country Status (7)

Country Link
US (2) US20150216849A1 (es)
EP (1) EP3102186B1 (es)
JP (2) JP6604957B2 (es)
CA (2) CA3214846A1 (es)
IL (2) IL247092B (es)
MX (1) MX2016010179A (es)
WO (1) WO2015120013A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214846A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and methods of treating alzheimer's disease
US20180042922A1 (en) * 2016-08-15 2018-02-15 Axovant Sciences Gmbh Compositions and methods of treating a neurodegenerative disease
WO2018153315A1 (zh) * 2017-02-23 2018-08-30 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
WO2020068731A1 (en) * 2018-09-25 2020-04-02 The General Hospital Corporation Methods for integrating cell gene expression data from multiple single-cell data sets and uses thereof
WO2020208398A1 (es) * 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10966989B2 (en) * 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
UA83645C2 (ru) 2002-10-24 2008-08-11 Мерц Фарма Гмбх Унд Ко. Кгаа Фармацевтический продукт, который содержит производное 1-аминоциклогексана и ингибитор ацетилхолинестеразы, его применение
CA2552221A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
RS51271B (sr) 2004-10-19 2010-12-31 Krka Tovarna Zdravil D.D. Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060160852A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
CA2604052C (en) * 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
US9029427B2 (en) * 2005-11-11 2015-05-12 Asahi Kasei Chemicals Corporation Controlled release solid preparation
GR20070100405A (el) 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
EP2211836A2 (en) 2007-10-10 2010-08-04 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI491395B (zh) 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CN102309465B (zh) * 2010-06-30 2015-04-22 天津药物研究院 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CA3214846A1 (en) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and methods of treating alzheimer's disease

Also Published As

Publication number Publication date
IL247092B (en) 2020-08-31
CA2938671A1 (en) 2015-08-13
JP6604957B2 (ja) 2019-11-13
US20180169082A1 (en) 2018-06-21
EP3102186B1 (en) 2021-01-27
EP3102186A4 (en) 2017-06-28
WO2015120013A1 (en) 2015-08-13
JP2017506624A (ja) 2017-03-09
IL247092A0 (en) 2016-09-29
IL276315A (en) 2020-09-30
US20150216849A1 (en) 2015-08-06
JP2020037556A (ja) 2020-03-12
CA3214846A1 (en) 2015-08-13
EP3102186A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2019012884A (es) Terapia de combinacion.
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2021002321A (es) Nuevos metodos.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2021002322A (es) Nuevos metodos.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
WO2020022976A3 (en) A formulation comprising dexketoprofen
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค